acute lymphoblastic leukemia in adolescents and young adults
Conditions
Interventions
intermediate risk (IR) group:treatment with IR protocol
High risk (HR)group:treatment with HR protocol
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
10 Years to 29 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed of ALL; (2) Patients aged 10-29 years (Note: Patients aged > 18 years are not included in Beijing Children's Hospital, Capital Medical University and Capital Pediatric Research Institute); (3) Patients who haven't received pre-treatment, except for those who receive single intrathecal injection or steriod for less than 7 days within 4 weeks before diagnosis; (4) Patients who have signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: (1) Mature type of lymphocytic leukemia; (2) Acute mixed phenotype leukemia; (3) Patients who only receive temporary chemotherapy, radiotherapy or immunotherapy, and do not receive systemic treatment according to the protocol; (4) Patients who use any antineoplastic therapy (chemotherapy or radiotherapy) within 2 weeks before enrollment, except for those who receive single intrathecal injection or hormones for less than 7 days within 4 weeks before diagnosis; (5) Pregnant; (6) Patients with a history of malignant tumors; (7) Patients with any obvious abnormal coexisting diseases or psychiatric disorders that may affect patients'life safety, compliance, informed consent, research participation, follow-up or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission state of Bone Marrow;Minimal Residual Disease;Overall survival;Event free survival;death;relapse; | — |
Countries
China
Contacts
Public ContactZheng Huyong
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed